An Introduction to Breast Cancer
New perspectives in cancer therapy have led to rapid progress in breast cancer research. Some of the most exciting recent developments include ongoing studies aiming to enhance current breast cancer screening options, as well as approval of several poly-ADP ribose polymerase (PARP) inhibitors. Other areas of active research include histone deacetylase (HDAC) inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Breast Cancer Content
Foreword – touchREVIEWS in Oncology & Haematology, Volume 18, Issue 2, 2022
Welcome to the latest edition of touchREVIEWS in Oncology & Haematology, which features a wealth of topical and practical content for oncologists and haematologists, as well as being of interest to the wider medical community. We open with an editorial by Joseph Franz and Sagar Lonial, looking at the potential of the ATLAS trial (ClinicalTrials.gov Identifier: […]
Matthew Goetz, ESMO 2022: MONARCH 3 trial – Interim overall survival results of abemaciclib + NSAI in patients with HR+, HER2- advanced breast cancer
The MONARCH 3 trial led to abemaciclib plus nonsteroidal aromatase inhibitor approval as initial therapy in postmenopausal patients with hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with significant improvement in progression-free survival. Prof. Matthew Goetz (Mayo Clinic, Rochester, MN, USA) joins touchONCOLOGY to discuss what the MONARCH 3 […]
Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancer
Dr Sara Tolaney joins touchONCOLOGY to discuss the latest clinical trial highlights in breast cancer, at ESMO 2022. She discusses the overall survival data from the TROPiCS-02 study, investigating sacituzumab govitecan-hziy versus treatment of physician’s choice in participants with HR+/HER2- metastatic breast cancer; and the overall survival data from the phase 3 MONARCH 3 trial, […]
Sara Tolaney, ESMO 2022: AMEERA-3 phase 2 study – Amcenestrant vs. endocrine treatment in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Amcenestrant is an optimized oral selective ER degrader (SERD), which is being investigated in the AMEERA-3 (NCT04059484), an open-label phase II randomized study. In this touchONCOLOGY interview, Dr Sara Tolaney (Dana-Farber Cancer Institute, and Brigham and Women’s Hospital, Boston, MA, USA) discusses the phase II study, investigating amcenestrant versus endocrine treatment of physician’s choice in patients […]
Oleg Gluz, ESMO 2022: Analysis of ADAPT and ADAPTcycle trials – Endocrine therapy response in breast cancer
The benefit of chemotherapy addition to endocrine therapy remains controversial in premenopausal patients. In this touchONCOLOGY interview Dr Oleg Gluz (West German Study Group, Mönchengladbach, Germany) discusses the ongoing phase III ADAPT cycle trial investigating the impact of age, recurrence score, and ovarian function suppression on endocrine therapy response. The abstract entitled ‘Impact of age, […]
Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies
touchREVIEWS in Oncology & Haematology 2022;18(2):98-102 DOI: https://doi.org/10.17925/OHR.2022.18.2.98
Triple-negative breast cancer (TNBC) is a biologically aggressive form of breast cancer defined by the absence of the oestrogen receptor and progesterone receptor, as well as lack of amplification of the human epidermal growth factor receptor 2 (HER2). TNBC accounts for up to 20% of breast cancers, and metastatic TNBC (mTNBC) is associated with worse […]
Judy King, ASCO 2022: Highlights in breast cancer clinical trials – DESTINY-Breast04, DESTINY-Breast03, TROPiCS-02, CDK4/6 trial data, MAINTAIN study
DESTINY-Breast04 investigates the use of trastuzumab deruxtecan, in the first randomized clinical trial to show that targeting HER2 provides clinically meaningful benefits for patients with HER2-low metastatic breast cancer (0:10). Dr Judy King (Royal Free Hospital, London, UK) joined touchONCOLOGY to discuss the DESTINY-Breast04 trial results and major highlights in breast cancer presented ASCO 2022. […]
Lynsey Drewett, AACR 2022: Olaparib in Combination With Neoadjuvant Platinum-based Chemotherapy – the PARTNER Study
It was a pleasure to speak with Dr Lynsey Drewett (University of Cambridge, Cambridge, UK) around the PARTNER study, investigating the efficacy and safety of the addition of olaparib to neoadjuvant platinum-based chemotherapy in the treatment of basal TNBC and/or gBRCA breast cancer. The abstract ‘PARTNER: Randomised, phase II/III trial to evaluate the safety and […]
Aditya Bardia, SABCS 2021: Results of EMERALD Phase III Trial
Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!